Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRA | P11474 | 4/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | PNLIP | P16233 | 5/20 | 0.66 |
| ▸ | RORC | P51449 | 5/20 | 0.65 |
| ▸ | PARG | Q86W56 | 1/20 | 0.62 |
| ▸ | STK39 | Q9UEW8 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | GCGR | P47871 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21295351 | 0.86 | PNLIP (0.63) | ESRRAPNLIPPARGSTK39POLB | |
| SCHEMBL11208256 | 0.86 | PNLIP (0.63) | ESRRAPNLIPPARGSTK39POLB | |
| SCHEMBL21295379 | 0.85 | PNLIP (0.66) | PNLIPPARGSTK39MEN1KMT2A | |
| SCHEMBL2170621 | 0.85 | ESRRA (0.71) | ESRRAPNLIPPARGSTK39MEN1 | |
| SCHEMBL11325646 | 0.84 | MAPT (0.55) | ESRRAALDH1A1RORCGAA | |
| SCHEMBL15223386 | 0.82 | MEN1 (0.68) | ESRRAALDH1A1PNLIPRORCSTK39 | |
| SCHEMBL10620277 | 0.82 | TDP1 (0.61) | ESRRAALDH1A1RORC | |
| SCHEMBL15067981 | 0.82 | STK39 (0.58) | ESRRAALDH1A1PNLIPRORCSTK39 | |
| SCHEMBL14384694 | 0.82 | TTR (0.60) | ESRRAALDH1A1MEN1KMT2APOLB | |
| Hydrochloric Acid SCHEMBL11326749 | 0.81 | TDP1 (0.59) | ESRRAALDH1A1RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6849632-B2 | Heteroaryl alkyl piperazine derivatives | CV THERAPEUTICS, INC. (US) | 2005-02-01 | — | — | US | disclosed |
| US-20040192702-A1 | Heteroaryl alkyl piperazine derivatives | ZABLOCKI JEFF (US) | 2004-09-30 | — | — | US | disclosed |
| US-20030216409-A1 | Heteroaryl alkyl piperazine derivatives | CV THERAPEUTICS, INC. | 2003-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192702-A1 | Heteroaryl alkyl piperazine derivatives | ATP2A1, CPT1B, ATP2A3 | ESRRA 2937/4885ALDH1A1 110/4885PNLIP 37/4885 |
| US-20030216409-A1 | Heteroaryl alkyl piperazine derivatives | ATP2A1, CPT1B, ATP2A3 | ESRRA 2937/4885ALDH1A1 110/4885PNLIP 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.